Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, Yang YT, Kommalapati A, Tella SH, DeAngelis C, Raisch DW, Sartor O, Hrushesky WJ, Ray PS, Yarnold PR, Love BL, Norris LB, Knopf K, Bobolts L, Riente J, Luminari S, Kane RC, Hoque S, Bennett CL.

Oncologist. 2019 Apr;24(4):537-548. doi: 10.1634/theoncologist.2018-0341. Epub 2019 Mar 6.

2.

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.

Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, Fu H, Claggett B, Wei LJ.

JAMA Oncol. 2017 Dec 1;3(12):1692-1696. doi: 10.1001/jamaoncol.2017.2797.

3.

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Sabol RA, Noxon V, Sartor O, Berger JR, Qureshi Z, Raisch DW, Norris LB, Yarnold PR, Georgantopoulos P, Hrushesky WJ, Bobolts L, Ray P, Lebby A, Kane RC, Bennett CL.

Cancer Med. 2017 Jul;6(7):1541-1551. doi: 10.1002/cam4.1098. Epub 2017 Jun 20. Review.

4.

Generic oncology drugs: are they all safe?

Yang YT, Nagai S, Chen BK, Qureshi ZP, Lebby AA, Kessler S, Georgantopoulos P, Raisch DW, Sartor O, Hermanson T, Kane RC, Hrushesky WJ, Riente JJ, Norris LB, Bobolts LR, Armitage JO, Bennett CL.

Lancet Oncol. 2016 Nov;17(11):e493-e501. doi: 10.1016/S1470-2045(16)30384-9. Review.

PMID:
27819247
5.

Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.

Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, MaCurdy TE, Houstoun M, Ryan Q, Wong S, Mott K, Sheu TC, Limb S, Worrall C, Kelman JA, Reichman ME.

JAMA. 2015 Nov 17;314(19):2062-8. doi: 10.1001/jama.2015.15572.

PMID:
26575062
6.

FDA Approval: Blinatumomab.

Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S, Mehrotra N, Ricks TK, Schmiel D, Song P, Zhao P, Zhou Q, Farrell AT, Pazdur R.

Clin Cancer Res. 2015 Sep 15;21(18):4035-9. doi: 10.1158/1078-0432.CCR-15-0612.

7.

Routine Iron Supplementation and Screening for Iron Deficiency Anemia in Pregnancy.

Kane RC.

Ann Intern Med. 2015 Sep 1;163(5):399-400. doi: 10.7326/L15-5132. No abstract available.

PMID:
26322707
8.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.

de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, Brower ME, Chang CJ, Pfuma E, Habtemariam B, Bullock J, Wang Y, Nie L, Chen XH, Lu DR, Al-Hakim A, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R.

Clin Cancer Res. 2015 Aug 15;21(16):3586-90. doi: 10.1158/1078-0432.CCR-14-2225.

9.

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.

Lee HZ, Kwitkowski VE, Del Valle PL, Ricci MS, Saber H, Habtemariam BA, Bullock J, Bloomquist E, Li Shen Y, Chen XH, Brown J, Mehrotra N, Dorff S, Charlab R, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R.

Clin Cancer Res. 2015 Jun 15;21(12):2666-70. doi: 10.1158/1078-0432.CCR-14-3119. Epub 2015 Mar 23.

10.

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.

Miller BW, Przepiorka D, de Claro RA, Lee K, Nie L, Simpson N, Gudi R, Saber H, Shord S, Bullock J, Marathe D, Mehrotra N, Hsieh LS, Ghosh D, Brown J, Kane RC, Justice R, Kaminskas E, Farrell AT, Pazdur R.

Clin Cancer Res. 2015 Apr 1;21(7):1525-9. doi: 10.1158/1078-0432.CCR-14-2522. Epub 2015 Feb 2.

11.

U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.

Lee HZ, Miller BW, Kwitkowski VE, Ricci S, DelValle P, Saber H, Grillo J, Bullock J, Florian J, Mehrotra N, Ko CW, Nie L, Shapiro M, Tolnay M, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R.

Clin Cancer Res. 2014 Aug 1;20(15):3902-7. doi: 10.1158/1078-0432.CCR-14-0516. Epub 2014 May 13.

12.

Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.

Basch E, Trentacosti AM, Burke LB, Kwitkowski V, Kane RC, Autio KA, Papadopoulos E, Stansbury JP, Kluetz PG, Smith H, Justice R, Pazdur R.

Cancer. 2014 Mar 1;120(5):761-7. doi: 10.1002/cncr.28470. Epub 2013 Dec 5.

13.

Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.

Autio KA, Bennett AV, Jia X, Fruscione M, Beer TM, George DJ, Carducci MA, Logothetis CJ, Kane RC, Sit L, Rogak L, Morris MJ, Scher HI, Basch EM.

J Oncol Pract. 2013 Sep;9(5):223-9. doi: 10.1200/JOP.2013.000876. Epub 2013 Jun 25.

14.

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, Habtemariam B, Bullock J, Bray JD, Hawes J, Palmby TR, Jee J, Adams W, Mahayni H, Brown J, Dorantes A, Sridhara R, Farrell AT, Pazdur R.

Clin Cancer Res. 2013 Sep 1;19(17):4559-63. doi: 10.1158/1078-0432.CCR-13-0755. Epub 2013 Jun 17.

15.

Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction.

Christian JB, Finkle JK, Ky B, Douglas PS, Gutstein DE, Hockings PD, Lainee P, Lenihan DJ, Mason JW, Sager PT, Todaro TG, Hicks KA, Kane RC, Ko HS, Lindenfeld J, Michelson EL, Milligan J, Munley JY, Raichlen JS, Shahlaee A, Strnadova C, Ye B, Turner JR.

Am Heart J. 2012 Dec;164(6):846-55. doi: 10.1016/j.ahj.2012.09.001. Epub 2012 Oct 26. Review.

16.

Caution in making inferences from FDA's Adverse Event Reporting System.

Auerbach M, Kane RC.

Am J Health Syst Pharm. 2012 Jun 1;69(11):922-3. doi: 10.2146/ajhp120138. No abstract available.

PMID:
22610021
17.

Re: potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.

Kane RC.

J Natl Cancer Inst. 2012 May 2;104(9):717-8; author reply 718. doi: 10.1093/jnci/djs164. Epub 2012 Apr 2. No abstract available.

PMID:
22472306
18.

Comparative effectiveness and health care spending.

Kane RC.

N Engl J Med. 2010 May 13;362(19):1845-6. doi: 10.1056/NEJMc1002540. No abstract available.

PMID:
20463349
19.

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R.

Oncologist. 2009 Jan;14(1):95-100. doi: 10.1634/theoncologist.2008-0185. Epub 2009 Jan 14. Review.

20.

The clinical significance of statistical significance.

Kane RC.

Oncologist. 2008 Nov;13(11):1129-33. doi: 10.1634/theoncologist.2008-0186. Epub 2008 Nov 4.

21.

Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy.

Kane RC, McGuinn WD Jr, Dagher R, Justice R, Pazdur R.

Oncologist. 2008 Apr;13(4):445-50. doi: 10.1634/theoncologist.2007-0247.

22.

Bortezomib for the treatment of mantle cell lymphoma.

Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4.

23.

Sorafenib for the treatment of advanced renal cell carcinoma.

Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R.

Clin Cancer Res. 2006 Dec 15;12(24):7271-8. Review.

24.
25.

Accuracy of a single fecal occult blood test in screening for colorectal cancer.

Kane RC.

Ann Intern Med. 2005 Aug 2;143(3):235. No abstract available.

PMID:
16061928
26.

Palliative care.

Kane RC.

N Engl J Med. 2004 Sep 9;351(11):1148-9; author reply 1148-9. No abstract available.

PMID:
15359433
28.

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Kane RC, Bross PF, Farrell AT, Pazdur R.

Oncologist. 2003;8(6):508-13. Review.

29.

Intravenous iron replacement with sodium ferric gluconate complex in sucrose for iron deficiency anemia in adults.

Kane RC.

Curr Ther Res Clin Exp. 2003 Apr;64(4):263-8. doi: 10.1016/S0011-393X(03)00038-9.

30.

Cellular telephones and brain tumors.

Kane RC.

N Engl J Med. 2001 Apr 26;344(17):1332. No abstract available.

PMID:
11336025
31.

Handheld cellular telephones and brain cancer risk.

Kane RC.

JAMA. 2001 Apr 11;285(14):1838; author reply 1838-9. No abstract available.

PMID:
11308389
32.

Blood transfusion for iron deficiency anemia.

Kane RC.

Am J Med. 1994 Apr;96(4):397. No abstract available.

PMID:
8166168
33.

Anemia and secondary hyperparathyroidism.

Kane RC.

Arch Intern Med. 1980 Jan;140(1):139. No abstract available.

PMID:
7352797
34.

Low dose elective brain irradiation in small cell carcinoma of the lung.

Beiler DD, Kane RC, Bernath AM, Cashdollar MR.

Int J Radiat Oncol Biol Phys. 1979 Jul;5(7):941-5. No abstract available.

PMID:
229091
35.

Treatment of advanced colorectal cancer with methyl-CCNU plus 5-day 5-fluorouracil infusion.

Kane RC, Cashdollar MR, Bernath AM.

Cancer Treat Rep. 1978 Oct;62(10):1521-5.

PMID:
709554
36.

Brain scans for metastasis.

Kane RC.

JAMA. 1978 May 19;239(20):2115-6. No abstract available.

PMID:
642149
37.

Phase II trial of streptozotocin for small cel anaplastic carcinoma of the lung.

Kane RC, Bernath AM, Cashdollar MR.

Cancer Treat Rep. 1978 Mar;62(3):477-8. No abstract available.

PMID:
206360
38.

Adriamycin therapy in American patients with hepatocellular carcinoma.

Ihde DC, Kane RC, Cohen MH, McIntire KR, Minna JD.

Cancer Treat Rep. 1977 Oct;61(7):1385-7. No abstract available.

PMID:
201380
39.

Fiberoptic bronchoscopy and culture bacteria from the lower respiratory.

Fossieck BE Jr, Parker RH, Cohen MH, Kane RC.

Chest. 1977 Jul;72(1):5-9.

PMID:
17516
40.
41.

Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma.

Kane RC, Cohen MH, Broder LE, Bull MI, Creaven PJ, Fossieck BE Jr.

Cancer Chemother Rep. 1975 Nov-Dec;59(6):1171-2. No abstract available.

PMID:
1222395
42.

Cytomegalovirus infection in a volunteer blood donor population.

Kane RC, Rousseau WE, Noble GR, Tegtmeier GE, Wulff H, Herndon HB, Chin TD, Bayer WL.

Infect Immun. 1975 Apr;11(4):719-23.

43.

Absence of bacteremia after fiberoptic bronchoscopy.

Kane RC, Cohen MH, Fossieck BE Jr, Tvardzik AV.

Am Rev Respir Dis. 1975 Jan;111(1):102-4.

PMID:
1111393
44.

Case reports. Diffuse skeletal and hepatic hemangiomatosis.

Kane RC, Newman AB.

Calif Med. 1973 Mar;118(3):41-4. No abstract available.

Supplemental Content

Support Center